Thermo Fisher Scientific heads into its May 20 Q1 results with the stock lagging a sharp sector rebound, the Street trimming targets across the board, and a closely watched earnings history that has punished disappointment hard.
The performance gap is the week's most striking data point. TMO closed at $466.76, down about 0.7% on the week. Close peers have moved in the opposite direction. CRL gained more than 11% over the same period. IQV added nearly 11%. RVTY rose more than 8%. RGEN climbed 7%. Against a peer group that was broadly recovering, TMO's relative weakness is hard to dismiss as sector noise — something specific is keeping buyers cautious.
That caution shows up clearly in options. The put/call ratio has drifted to 1.31, a fraction above its 20-day average of 1.28 — not dramatically elevated, and well below the 52-week high of 2.27, but the direction of travel since late March is notable. The PCR has been creeping higher as the stock has weakened, suggesting incremental demand for downside hedges rather than outright panic. Short interest is not the driver here. It runs at just 1.18% of the free float, down about 1.3% on the week and drifting sideways over 30 days after a modest April build. Borrow availability is extremely loose — lending conditions offer no squeeze pressure whatsoever. The positioning story is one of defensive options hedging, not a conviction short thesis.
The Street is broadly constructive but has been steadily marking down expectations since earnings. After Q1 results on April 23 sent the stock down roughly 8.6% in a single session — and nearly 7% over the subsequent five days — analysts maintained positive ratings while cutting price targets. Stifel trimmed to $600 from $700. Baird lowered to $639 from $653. Barclays reduced to $625 from $650. Evercore ISI moved to $575 from $650 before the print. The mean target of $620 implies meaningful upside from current levels, but that figure was set before the April sell-off fully settled and before the May 20 event reshapes the picture. Bulls point to Thermo Fisher's life sciences solutions segment, projected to grow at a 5%-plus compound rate, and its CRO build-out through the Clario acquisition as longer-term structural drivers. Bears note that adjusted EBIT margins have compressed by more than 800 basis points since 2021 and that biotech funding conditions remain soft — a meaningful headwind to the instrument and reagent demand that underpins near-term revenue.
Institutional ownership is dense and largely passive. Vanguard holds 9.2% of shares, BlackRock 8.2%, State Street 4.5%. The notable active names — T. Rowe Price, Fidelity — each added material positions in the most recent reporting period, with T. Rowe up by 2.5 million shares and Fidelity adding 2.1 million. That incremental buying from fundamental managers, even into a deteriorating tape, suggests the long-side conviction is not cracking. Insider activity is less encouraging in isolation — CEO Marc Casper sold roughly $1.4 million in March shares across multiple tranches, and President/COO Gianluca Pettiti sold a modest $185,000 block in late April — but the volumes are small relative to the company's scale and all transactions carried a low significance score.
The earnings history is the sharpest context for what comes next. The April 23 report produced an 8.6% single-day drop and a nearly 7% five-day loss. The prior event, in January, was even more severe: down 11% on the day and 11% over five days. Two consecutive prints with that kind of reaction shape the way options traders are likely to think about May 20. Whether the print on that date shifts the trajectory — or repeats the pattern — is what the market is pricing around now.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
